Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine + Immunotherapy in Advanced EGFR-negative NSCLC
NCT06554613Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olanzapine in non-small cell lung cancer (NSCLC), sponsored by The Second Affiliated Hospital of Nanchang University. Started Jul 2024; status: recruiting.
02
Drugs
olanzapine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06554613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554613.